N. Jeyin, G. Kidane, D. Withers, S. Ball, K. Tarver
{"title":"COVID-19大流行期间非小细胞肺癌(NSCLC)的低分割根治性放疗的真实世界经验:具有可接受的无进展(PFS)和总生存期(OS)的耐受性良好的放疗方案","authors":"N. Jeyin, G. Kidane, D. Withers, S. Ball, K. Tarver","doi":"10.1016/S0169-5002(23)00572-X","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":153842,"journal":{"name":"Lung Cancer (Amsterdam, Netherlands)","volume":"245 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS)\",\"authors\":\"N. Jeyin, G. Kidane, D. Withers, S. Ball, K. Tarver\",\"doi\":\"10.1016/S0169-5002(23)00572-X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":153842,\"journal\":{\"name\":\"Lung Cancer (Amsterdam, Netherlands)\",\"volume\":\"245 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer (Amsterdam, Netherlands)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/S0169-5002(23)00572-X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer (Amsterdam, Netherlands)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/S0169-5002(23)00572-X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS)